- Home
- FAMI vs APVO Comparison
FAMI vs APVO Comparison
Compare FAMI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- APVO
- Stock Information
- Founded
- FAMI 2015
- APVO 2016
- Country
- FAMI China
- APVO United States
- Employees
- FAMI N/A
- APVO N/A
- Industry
- FAMI Packaged Foods
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- FAMI Consumer Staples
- APVO Health Care
- Exchange
- FAMI Nasdaq
- APVO Nasdaq
- Market Cap
- FAMI 3.4M
- APVO 3.7M
- IPO Year
- FAMI 2018
- APVO N/A
- Fundamental
- Price
- FAMI $0.28
- APVO $0.31
- Analyst Decision
- FAMI
- APVO Strong Buy
- Analyst Count
- FAMI 0
- APVO 1
- Target Price
- FAMI N/A
- APVO $8.00
- AVG Volume (30 Days)
- FAMI 544.2K
- APVO 3.1M
- Earning Date
- FAMI 11-29-2024
- APVO 11-07-2024
- Dividend Yield
- FAMI N/A
- APVO N/A
- EPS Growth
- FAMI N/A
- APVO N/A
- EPS
- FAMI 0.13
- APVO N/A
- Revenue
- FAMI $86,261,500.00
- APVO N/A
- Revenue This Year
- FAMI N/A
- APVO N/A
- Revenue Next Year
- FAMI N/A
- APVO N/A
- P/E Ratio
- FAMI $2.28
- APVO N/A
- Revenue Growth
- FAMI N/A
- APVO N/A
- 52 Week Low
- FAMI $0.17
- APVO $0.14
- 52 Week High
- FAMI $2.35
- APVO $10.80
- Technical
- Relative Strength Index (RSI)
- FAMI 46.10
- APVO 58.05
- Support Level
- FAMI $0.28
- APVO $0.20
- Resistance Level
- FAMI $0.32
- APVO $0.33
- Average True Range (ATR)
- FAMI 0.03
- APVO 0.04
- MACD
- FAMI -0.00
- APVO 0.00
- Stochastic Oscillator
- FAMI 44.44
- APVO 82.58
About FAMI Farmmi Inc.
Farmmi Inc is a supplier of agricultural products. The products of the company are Shiitake Mushroom, Mu Er Mushroom and other edible fungi and other agricultural products. The majority of products are sold in mainland China.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.